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Abstract
Objectives To correlate hepatic and splenic CT perfusion pa-
rameters with hepatic venous pressure gradient (HVPG) mea-
surements in patients with cirrhosis.
Methods Twenty-one patients with cirrhosis (males, 17; fe-
males, 4; mean ± SD age, 57 ± 7 years) underwent hepatic
and splenic perfusion CT on a 320-detector row volume scan-
ner as well as invasive measurement of HVPG. Different CT
perfusion algorithms (maximum slope analysis and Patlak plot)
were used to measure hepatic arterial flow (HAF), portal ve-
nous flow (PVF), hepatic perfusion index (HPI), splenic arterial
flow (SAF), splenic blood volume (SBV) and splenic clearance
(SCL). Hepatic and splenic perfusion parameters were correlat-
ed with HVPG, and sensitivity and specificity for detection of
severe portal hypertension (≥12 mmHg) were calculated.
Results The Spearman correlation coefficient was −0.53
(p < 0.05) between SAF and HVPG, and −0.68 (p < 0.01) be-
tween HVPG and SCL. Using a cut-off value of 125 ml/min/
100 ml for SCL, sensitivity for detection of a HVPG of
≥12 mmHg was 94%, and specificity 100%. There was no
significant correlation between hepatic perfusion parameters
and HVPG.
Conclusion CT perfusion in patients with cirrhosis showed a
strong correlation between SCL and HVPG and may be used
for detection of severe portal hypertension.
Key points
• SAF and SCL are statistically significantly correlated with
HVPG
• SCL showed stronger correlation with HVPG than SAF
• 125 ml/min/100 ml SCL-cut-off yielded 94% sensitivity,
100% specificity for severe PH
• HAF, PVF and HPI showed no statistically significant cor-
relation with HVPG
Keywords CT-perfusion . Liver . Spleen . Cirrhosis . Portal
hypertension
Abbreviations and acronyms
HAF Hepatic arterial flow (ml/min/100 ml)
HPI Hepatic perfusion index (%)
HVPG Hepatic venous pressure gradient (mmHg)
PH Portal hypertension
PVF Portal venous flow (ml/min/100 ml)
SAF Splenic arterial flow (ml/min/100 ml)
SBV Splenic blood volume (ml/100 ml)
SCL Splenic clearance (ml/min/100 ml)
Introduction
Portal hypertension (PH) is defined as an increase in the pres-
sure in the portal vein and its territory, and is one of the main
causes of severe complications and death in patients with cir-
rhosis and, therefore, the main prognostic factor in cirrhosis [1].
In normal fasted subjects at rest and in the supine position,
portal pressure ranges from 7 to 12 mmHg [2]. The direct
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measurement of portal pressure is a markedly invasive
technique that is no longer performed in patients with cirrhosis;
the indirect, less invasive technique of measuring the hepatic
venous pressure gradient (HVPG) is used as a standard of
reference to estimate the severity of PH in cirrhosis. In healthy
subjects, the pressure gradient between the portal vein territory
and the vena cava territory ranges from 1 to 4 mmHg [3]. PH is
considered moderate when the HVPG ranges from 5 to
10 mmHg and severe when the HVPG is greater than
10–12 mmHg. [1, 4, 5]. An HVPG threshold of 10 mmHg is
termed clinically significant PH as it predicts the risk of
complications such as formation of oesophageal varices and
development of hepatocellular carcinoma [6–8]. An HVPG
>12 mmHg is associated with the risk of variceal bleeding [4]
and an HVPG >16 mmHg correlates with increased mortality
[9, 10].
Although HVPG measurement is a safe technique with
only minor complications in <1% of patients [1], non-
invasive techniques for HVPG assessment would be more
favourable than invasive techniques. Computed tomography
perfusion imaging (CTP) is a functional imaging technique
that has been proven to allow quantification of the hepatic
blood circulation in patients with diffuse liver disease
[11–13]. As the hepatic blood circulation is commonly affect-
ed by chronic liver disease, mainly due to parenchymal
remodeling resulting in an increased vascular resistance of
the liver, CTP may be a valuable tool for noninvasive assess-
ment of PH. In addition, splenic blood circulation assessed by
CTP may be influenced by PH.
The aim of this study was to evaluate whether a correlation
exists between hepatic and splenic perfusion parameters




This prospective study was approved by the Institutional
Ethics Committee and informed consent was obtained
from all patients. Patients who underwent HVPG mea-
surement for evaluation of liver transplantation underwent
CTP of the liver and the spleen. Inclusion criteria were:
(a) HVPG measurement for suspected portal hypertension,
and (b) age 18 years or older. Exclusion criteria were: (a)
renal impairment (estimated glomerular filtration rate
(eGFR) <45 ml/min/1,73 qm), (b) other contraindications
to the application of iodinated contrast media, and (c)
pregnancy.
Twenty-one patients (18male, three female; mean ± SD age,
57 ± 7 years; range, 41–69 years) were included in the study.
Twenty patients had cirrhosis and one patient had
neuroendocrine liver metastases. Of the patients with cirrhosis,
Child-Pugh classification was A in two patients, B in eight
patients and C in eight patients. In two patients no classification
was available in the medical records. Fourteen patients had
alcoholic cirrhosis, three patients had cirrhosis due to hepatitis
C and three patients had cryptogenic cirrhosis.
All patients underwent CTP of the liver and the spleen as well
as HVPG measurement. The mean period (±SD) between CTP
and HPGV measurement was 2 ± 2 days (range, 0–9 days).
CTP imaging technique
All VCTP studies were performed using a 320-detector row
CT (Aquilion One, Toshiba Medical Systems, Otawara,
Japan) following an overnight fast. Scanning parameters were
as follows: 100 kV tube voltage, 100 mA tube current, 0.5 s
gantry rotation time and 320 x 0.5-mm section thickness. The
detector width was 16 cm. A low-dose pre-contrast helical
scan of the abdomen during suspended respiration following
inspiration was performed to locate the liver and the spleen
and to plan the scan position for the CTP study. As recom-
mended for CT-angiography, contrast dose and injection rate
were adjusted to patients’ body weight in our CT-perfusion
protocol [14] (40–60 ml: 50–69 kg body weight, 40 ml; 70–
89 kg body weight, 50 ml; and >90 kg body weight,
60 ml).Iomeprol 400 mgI/ml (Iomeron®, Bracco, Milano,
Italy) was injected at a flow rate of 6–8 ml/s (50–69 kg body
weight, 6 ml/s; 70–89 kg body weight, 7 ml/s; and >90 kg
body weight, 8 ml/s), followed by the same volume of saline
solution at the same injection rate using a dual-head power
injector (Ulrich Medical, Chesterfield, MO, USA). All in all
21 volume acquisitions were obtained without table move-
ment in all patients. After acquisition of two pre-contrast vol-
umes, eight volumes were acquired during the early period of
the injection protocol with an interscan gap of 1 s followed by
seven volume acquisitions with an interscan gap of 2 s and by
further four volume acquisitions with an interscan gap of 4 s.
Total scan time was 80 s. Every patient was instructed to
breathe normally during the examination and to avoid deep
and irregular breathing. A band compressing the upper abdo-
men was used to reduce liver excursions. The total dose-
length product (DLP) of 21 volumes was 1,031.1 mGy.cm,
which is equivalent to an effective dose of 15.4mSv (k 0.015).
Image analysis
Post-processing was performed using body perfusion software
(Body Perfusion, Toshiba Medical Systems) as available on
the CT equipment. First, body registration to correct motion
between the dynamic volumes was performed. Following reg-
istration, the corrected volumes were loaded into the body
perfusion software.
Eur Radiol
The dual input maximum slope model [15] was used
for perfusion analysis of the liver. Two methods were
used with regard to the settings of the regions of interest
(ROIs) in all patients. In Method I the ROIs were man-
ually placed in the abdominal aorta, the portal vein, the
spleen and normal liver parenchyma to generate respec-
tive time-density curves (TDCs). The generated TDCs
represented the hepatic artery input function and the por-
tal vein input function, respectively (Fig. 1A). The peak
point of the generated TDC of the spleen is used to
separate the hepatic artery circulation before the peak
point and the portal vein circulation after the peak point,
respectively. In Method II the break point was manually
set at the crossing point of the aortal and portal venous
TDC (Fig. 1B). This adapted method was performed as it
has been shown that in patients with portal venous hy-
pertension peak splenic enhancement may be delayed,
which may alter perfusion measurements due to inaccu-
rate separation of arterial and portal venous perfusion
[16]. Hepatic arterial blood flow (HAF; ml/min/
100 ml), portal venous blood flow (PVF; ml/min/
100 ml), as well as the hepatic perfusion index (HPI;
HAF/(HAF + PVF); %) were calculated for all liver seg-
ments and the results were averaged for the whole liver.
The single input maximum slope and the Patlak plot
model [15] were used for perfusion analysis of the
spleen. ROIs were manually placed in the abdominal
aorta and the spleen to generate respective TDCs. With
the use of the single input maximum slope model the
splenic arterial blood flow (SAF; ml/min/100 ml) and
with the Patlak plot model, the splenic blood volume
(SBV; ml/100 ml) and the splenic clearance (SCL; ml/
min/100 ml), which is the total flux from the intravascu-
lar space to the extravascular space, were calculated.
In addition to CT-perfusion parameters, morphological
features such as presence of perihepatic ascites,
portosystemic collateral vessels and portal thrombosis
were qualitatively assessed and spleen volume was quan-
titatively assessed using semiautomatic volumetric soft-
ware (Vitrea, Toshiba Medical Systems).
HVPG measurement
HVPG measurements were carried out according to
established standards [17] following an overnight fast.
Under ultrasound guidance, the right internal jugular vein
was cannulated and a 7-French balloon catheter (Boston
Scientific) was guided into the right hepatic vein for the mea-
surement of wedged and free hepatic venous pressures. HVPG
was calculated from the difference between wedged hepatic
venous pressure (WHVP) and free hepatic venous pressure,
and the mean of triplicate measurements was computed.
Statistical analysis
The data were descriptively reviewed. The significances of
differences in medians between Method I and Method II were
analysed using Wilcoxon’s test. Spearman’s test was used for
correlation of the perfusion parameters with the HVPG.
Comparison of the parameters between the severe
(≥12 mmHg) and moderate (<12 mmHg) portal hypertension
groups and between patients with and without portal throm-
bosis was assessed using the Mann-Whitney test. Receiver
operating characteristics (ROC) analysis was performed to
calculate cut-off values for differentiation between moderate
and severe portal hypertension. The significance of distribu-
tion of morphological features between the two groups was
tested using the Chi-square test. Statistical analysis was per-
formed with commercially available software (IBM SPSS
Statistics, Version 23, SPSS Inc., Chicago, IL, USA). A P-
value <0.05 was considered statistically significant.
Results
Details on hepatic and splenic perfusion values and HVPG are
listed in Table 1.
There was no statistically significant difference between
Method I and Method II in HAF, whereas PVF and HPI were
statistically significant different (p < 0.05). The mean differ-
ence in medians (±SD) was 1.0 ± 2.3 ml/min/ml for HAF
(range, 0–9.1 ml/min/100 ml), 22.6 ± 43.3 ml/min/100 ml for
PVF (range, 0–146.1 ml/min/100 ml) and 9.1 ± 14.4 ml/min/
100 ml for HPI (range, 0–41.6 ml/min/100 ml).
For Method I as well as for Method II no statistically sig-
nificant correlation was found between HAF, PVF, HPI and
HVPG. On the contrary, SAF and SCL showed a statistically
significant negative correlation with the HVPG, whereas SBV
showed no correlation. The Spearman correlation coefficient
was −0.53 (p < 0.05) for SAF and −0.68 (p < 0.01) for SCL.
Figure 2 shows scatter plots for SAF and HVPG and for SCL
and HVPG, respectively. There was no statistically significant
correlation between splenic volume and HVPG.
Five patients had moderate (HVPG <12 mmHg) and
16 patients had severe (HVPG ≥12 mmHg) portal hyper-
tension. The median HVPG was 7 mmHg (interquartile
range (IQR), 8 mmHg; range, 2–11 mmHg) in the mod-
erate portal hypertension group and 16 mmHg (IQR,
8 mmHg; range, 12–28 mmHg) in the severe portal hy-
pertension group. Child-Pugh classification was A in one
patient, B in two patients and C in one patient in the
moderate portal hypertension group. One patient of this
group had no cirrhosis. In the severe portal hypertension
group Child-Pugh classification was A in one patient, B
in six patients and C in seven patients. In two patients of
this group Child-Pugh classification was not available.
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Body weight did not significantly differ between the two
groups. Median body weight was 64 kg (range, 60–
109 kg) in the moderate portal hypertension group and
81.5 kg (range, 60–110 kg) in the severe portal hyper-
tension group.
SCL was statistically significantly different in patients with
moderate and those with severe portal hypertension (P < 0.01),
whereas SAF was not different between the two groups.
Median SCL in patients with moderate portal hypertension
was 133.2 ml/min/100 ml (IQR, 20.7; range, 127.8–160.8 ml/
Fig. 1 (A–D) Dual input maximum slope model of the liver yielding
time-density-curves (TDC) for the aorta, the portal vein, the spleen and
the liver (A, B) and parametric images (C, D) for hepatic arterial flow
(HAF; left top), portal venous flow (PVF; right top) and hepatic perfusion
index (HPI; left bottom) as well as corresponding pre-contrast grey-scale
images (right bottom). The peak point of the TDC of the spleen is used to
separate the hepatic artery circulation before the peak point and the portal
vein circulation after the peak point, respectively. In patients with
cirrhosis, the TDC of the liver may be flattened with a delayed peak
(A). Perfusion calculation with this setting led to very low PVF and very
high HPI (C). Manual adaptation with placement of the breakpoint at the
crossing point of the aortal and portal venous TDC (B) led to significantly
higher PVF and lower HPI (D). HAF, PVF and HPI in this patient were
68.5 ml/min/100 ml, 51.2 ml/min/100 ml and 61.4% for the standard
setting (A, C), and 71.4 ml/min/100 ml, 126.5 ml/min/100 ml and
38.1% for the manual adapted setting (B, D). Severe portal hypertension
(HVPG 22mmHg) may contribute to the flat shape of the splenic TDC in
this patient. SP start point, EP end point, SM spleen maximum
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min/100ml); in patients with severe portal hypertensionmedian
SCL was 74.1 ml/min/100 ml (IQR, 51.8, range, 23.4–138.6 ml/
min/100 ml).
ROC analysis of SCL for differentiation between moderate
and severe portal hypertension showed an area under the
curve of 0.96 with a standard error of 0.04 (95% confidence
interval (CI), 0.88–1) (Fig. 3). Using a cut-off value of 125 ml/
min/100 ml for SCL, sensitivity for detection of severe portal
hypertension was 94% with a specificity of 100%.
Perihepatic ascites was present in three patients with mod-
erate portal hypertension and in seven patients with severe
portal hypertension; portal systemic varicose collateral vessels
were present in three patients with moderate portal hyperten-
sion and in six patients with severe portal hypertension; and
portal vein thrombosis was present in none of the patients with
moderate portal hypertension and in four patients with severe
portal hypertension. The distribution of these morphological
parameters between patients with moderate and those with
severe portal hypertension was not statistically significant.
There was no statistically significant difference in splenic per-
fusion parameters and in HVPG between patients with and
those without portal thrombosis. The median SAF was
93 ml/min/100 ml (IQR, 65.6; range, 77.3–163 ml/min/
100 ml) in patients with portal thrombosis and 109.8 ml/
min/100 ml (IQR, 56.2; range, 67.2–209.2 ml/min/100 ml)
in patients without portal thrombosis. The corresponding
values were 1.9 ml/100 ml (IQR, 1.4; range 1.2–2.7 ml/
100 ml) and 1.5 ml/100 ml (IQR, 3.8; range, 0.4–39.9 ml/
Fig. 2 (A,B) Correlation between splenic arterial flow (SAF) and hepatovenous pressure gradient (HVPG) (A) and splenic clearance (SCL) and HVPG
(B) showing a moderate negative correlation (r = 0.53. p < 0.05) for SAF and strong negative correlation (r = 0.68, p < 0.01) for SCL, respectively
Table 1 Details of hepatic and
splenic perfusion parameters,
splenic volume and HVPG
Median IQR Min Max
Liver Method I
HAF (ml/min/100 ml) 56.7 26.2 26.4 123.9
PVF (ml/min/100 ml) 118.0 81.9 31.1 255.8
HPI (%) 35.9 26.7 16.0 81.7
Method II
HAF (ml/min/100 ml) 56.7 30.3 26.4 121.2
PVF (ml/min/100 ml) 134.1 62.6 93.1 255.8
HPI (%) 35.5 16.0 16.0 48.0
Spleen SAF (ml/min/100 ml) 107.8 56.4 67.2 209.2
SBV (ml/100 ml) 1.5 2.3 0.4 39.9
SCL (ml/min/100 ml) 86,4 69 23.4 160,8
V (ml) 577.1 435.0 149.4 1274.1
HVPG (mmHg) 14 9 2 28
HAF hepatic arterial flow, PVF portal venous flow, HPI perfusion index, SAF splenic arterial flow, SBV splenic
blood volume, SCL splenic clearance, V volume, HVPG hepatic venous pressure gradient
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100 ml) for SBV, and 79.8 ml/min/100 ml (IQR, 59.8; range,
66–138.6 ml/min/100 ml) and 86.4 ml/min/100 ml (IQR,
79.5; range, 23.4–160.8 ml/min/100 ml) for SCL. Median
HVPG was 19.5 mmHg (IQR, 11; range 13–25 mmHg) in
patients with portal thrombosis, and 14mmHg (IQR, 9; range,
2–28 mmHg) in those without portal thrombosis.
Discussion
Our study results showed a strong negative correlation be-
tween SCL and HVPG and a moderate negative correlation
between SAF and HVPG. Using a SCL cut-off value of
125 ml/min/100 ml sensitivity for detection of severe PH
(≥12 mmHg) was 94%, and specificity was 100%. This indi-
cates that perfusion CT of the spleen with calculation of the
clearance which is the total flux of the contrast media from the
intravascular space to the extravascular space in ml/min per
100 ml of tissue may be a non-invasive tool for estimation of
the HVPG. We assume that a high portal venous pressure
increases the pressure within the splenic interstitium which
contradicts the flux of iodine from the intravascular space to
the extravascular interstitial space. The correlation between
SAF and HVPG is in accordance with the limited literature.
In a study by Tsushima et al. [18], the authors reported a lower
SAF in patients with chronic liver disease than in a control
group and also found a significant negative correlation be-
tween SAF andWHVP in 11 patients. In contrast to our study,
the correlation between SAF and WHVP was strong
(r = 0.741, p = 0.0024), whereas in our study the correlation
between SAF and HVPG was moderate. However, another
study [19] failed to show a statistically significant difference
in SAF between patients with and patients without cirrhosis,
although a trend toward lower perfusion in patients with cir-
rhosis was observed. In a study by Sauter et al. [20] on dy-
namic contrast-enhanced splenic CT in patients with and with-
out cirrhosis, splenic BV and K(trans), which is a parameter
used in different perfusion software and which is comparable
to SCL, were statistically significant different between the two
groups, which is for K(trans) in accordance with our study.
However, no correlation with HVPG was performed in the
study by Sauter et al. [20].
The liver perfusion parameters did not correlate with
HVPG and failed to separate patients with severe PH from
patients with moderate PH. To the best of our knowledge, no
data are available in the literature on hepatic CT perfusion in
patients with PH. However, several studies assessed perfusion
with scintigraphy and a clear reduction of portal perfusion was
shown in patients with PH compared to healthy patients
[21–23]. The sensitivity of scintigraphy in detecting PH,
based on a portal contribution of ≤66%, was 62%, and spec-
ificity was 100%. Portal contribution to liver perfusion was
statistically significantly negative correlated to HVPG
(r = −0.43) [22]. We could not reproduce this finding in our
CT perfusion study. Using contrast-enhanced ultrasonogra-
phy, Jeong et al. [24] reported that the intrahepatic transit time,
which is the time from hepatic arterial arrival to hepatic ve-
nous arrival, moderately correlated with HVPG (r = −0.613)
and that this parameter was the most accurate one to diagnose
severe PH (≥12 mmHg). Using a cut-off value of 6 s, sensi-
tivity was 91% and 85%, and specificity was 89% and 78%,
respectively, for the two reviewers. The false-positive rate was
only 2%; however, the false-negative rates were 35% and
40%, respectively. With the software used in our study, the
intrahepatic transit time was not available and this parameter
could not be compared to the literature. In a recent study by
Annet et al. [25] on hepatic flow parameters measured with
MR imaging, HVPGwas significantly correlated with all flow
parameters. The correlation was substantial for the portal frac-
tion (r = −0.769, p ≤ .001), the apparent portal perfusion
(r = −0.726, p ≤ .001), and the mean transit time (r = 0.721,
p ≤ .001). Weak but significant correlations were found for
apparent arterial perfusion (r = 0.542, p ≤ .001), and distribu-
tion volume (r = 0.437, p ≤ .002). In contrast, no significant
association was found between HVPG and the portal flow in
a study by Gouya et al. [26], whereas the azygos flow and
HVPG were significantly correlated. The different imaging
techniques with different models of perfusion calculation
may contribute to the inconsistent results.
Splenic volume was not significantly correlated to HVPG
in our study. This is in contrast to a study by Kihira et al. [27]
which showed such a correlation. However, the correlation
Fig. 3 Receiver operating characteristic (ROC) curves of for
differentiation between moderate and severe portal hypertension (PH)
splenic clearance (SCL) for identifying severe PH. Area under the ROC
was 0.96 (standard error, 0.04; 95% CI, 0.88–1)
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coefficient was only weak (0.32) in that study. In a recent
study by Pickhardt et al. [28] splenic volume allowed for
non-invasive staging of hepatic fibrosis, but this finding may
not be transferable to patients with cirrhosis and different
levels of portal hypertension.
Using different ROI settings for separation between HAF
and PVF led to significant differences in PVF and HPI calcu-
lation in our patients. This is in accordance with a study by
Fischer et al. [16], which showed that peak splenic enhance-
ment, which defines the break point between HAF and PVF, is
delayed in patients with PH, resulting in a miscalculation of
hepatic perfusion parameters. The authors recommended
using peak renal enhancement instead of peak splenic en-
hancement in patients with PH. In our study, the break point
was manually set at the crossing point of the aortal and portal
venous TDC, which indicates the time point of replacement of
the HAF by the PVF. We believe that this may be a more
accurate method for hepatic blood flow separation than using
a ROI within the renal parenchyma.
The small number of patients which may have influenced
the results and overestimated sensitivity and specificity in de-
tection of severe PH has to be considered as a limitation of this
study. However, the standard error of the AUC in ROC anal-
ysis was only 0.04 and consequently a larger study cannot
completely contradict our results. Only improvements of the
estimates of the level of sensitivity and specificity will occur.
Further studies are needed to confirm our first promising find-
ings. The limitation of the results to the specific type of CT
scanner, software, scan protocol and injection protocol used in
this study has to be considered as further limitation of the
study. Parameter values from our study cannot be transferred
to CT perfusion using different models of perfusion calcula-
tion. In addition, other perfusion parameters such as mean
transit time were not available in the used model and could
not be assessed.
In conclusion, on CT-perfusion in patients with PH, SCL
showed a strong correlation with HVPG and may be used as a
parameter for detection of severe PH.
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